Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

A clinical study of MK-8527 in people with HIV-1 (MK-8527-004)

This research study, called MK-8527-004, is testing a new medicine, MK-8527, for people who have HIV-1. HIV-1 is a virus that can weaken your immune system over time. This particular study is in its very early stages, sometimes called Phase 1. This means scientists are trying to learn how the new medicine behaves in the human body, such as how it's absorbed, distributed, and processed. They also want to check if it's safe for people to take. The goal is to see if this new medicine could be a helpful treatment option for HIV-1 in the future.

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Merck Sharp & Dohme LLC

Enrolment target

Start

16 Jun 2023

HIV-1 (Human Immunodeficiency Virus Type 1)

What is this study about?

This study is about a new medicine called MK-8527. It's being tested for people who have HIV-1. HIV-1 is a virus that gradually weakens your body's ability to fight off illnesses. Scientists are always working to find new and better ways to manage HIV-1, as well as looking for new treatments to help people live healthier lives.

This specific study, known as MK-8527-004, is in the very first steps of testing a new medicine in people. This early stage is often called 'Phase 1'. At this point, the main aims are to understand how the medicine works in the human body. This includes questions like: How much medicine should be given? How does the body absorb it? How long does it stay in the body? And most importantly, what are the possible side effects and is it safe?

The information gathered from studies like this is really important. It helps doctors and scientists decide if a new medicine is promising enough to be tested in more people later on. While this study won't tell us if MK-8527 can cure HIV-1, it's a crucial step in finding potentially new and effective treatments to help people living with the condition.

Key takeaways

This study is testing a new medicine called MK-8527 for HIV-1.
It's an early-stage (Phase 1) study focused on safety and how the medicine works in the body.
It's open to adults aged 18 and older, both men and women, with HIV-1.
Participation involves taking the medicine and attending regular clinic visits.
The goal is to gather information that could lead to new HIV-1 treatments in the future.

Who may be eligible?

To join this study, you need to be an adult, aged 18 or older. There is no upper age limit, meaning older adults can also take part.

This study is open to both men and women. The researchers want to include a wide range of people to get a good understanding of how the new medicine works.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have HIV-1?
Are you a man or a woman?
Are you able to attend regular clinic appointments?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would be given the new medicine, MK-8527. Because this is an early-stage study, you would likely have several visits to the clinic. These visits are important for the medical team to keep a close eye on your health and how you react to the medicine. They might involve blood tests, physical examinations, and answering questions about how you're feeling.

The exact duration of the study and how many visits you would need isn't detailed here, but early-stage studies often involve more frequent check-ups at the beginning. You would be given all the specific details about the schedule before you decide to join. The goal is to carefully understand the new medicine's effects in people.

Potential risks and benefits

Taking part in any medical study has both possible benefits and risks. A potential benefit could be helping researchers learn more about a new treatment for HIV-1, which could help future patients. You might also receive close medical attention during the study. However, there's no guarantee that the new medicine will help your condition, and there could be unknown side effects. You will always have the right to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Romania

Common questions

What is HIV-1?

HIV-1 is a virus that, over time, can weaken your immune system, making it harder for your body to fight off infections and diseases.

What does 'Phase 1' mean for a study?

Phase 1 means it's one of the first times this new medicine is being tested in people. The main goals are to check how safe it is and how it works in the body.

Will this study cure my HIV-1?

This early-stage study is not designed to find a cure. Its purpose is to gather basic information about a new medicine's safety and how it is processed by the body.

Who can join this study?

Adults aged 18 and over, both men and women, who have HIV-1 can be considered for this study. Other specific health requirements would also apply.

What kind of commitment is involved?

Taking part would involve receiving the study medicine and having regular visits to the clinic for tests and check-ups to monitor your health and the medicine's effects.